Quarterly report [Sections 13 or 15(d)]

Sponsored Research and License Agreements (Details)

v3.26.1
Sponsored Research and License Agreements (Details) - USD ($)
1 Months Ended 3 Months Ended 28 Months Ended
Apr. 30, 2021
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Mar. 31, 2026
Dec. 31, 2025
Jan. 31, 2024
Dec. 31, 2023
Collaborations                
Upfront payment received $ 125,000,000.0              
Revenue recognized   $ 58,818,000   $ 53,333,000        
ocadusertib                
Collaborations                
Company's percentage of development costs   20.00%            
Revenue recognized     $ 40,000,000.0          
Deferred revenue   $ 0     $ 0 $ 0    
Grifols                
Collaborations                
Deferred revenue   0     0 0    
Grifols | Royalty                
Collaborations                
Revenue recognized   1,800,000   1,400,000        
Kissei                
Collaborations                
Deferred revenue   0     0 0    
Revenue recognized   1,800,000   1,600,000        
Kissei | fostamatinib                
Collaborations                
Deferred revenue   1,400,000   3,000,000.0 1,400,000 1,400,000    
Medison | fostamatinib                
Collaborations                
Revenue recognized   300,000   400,000        
Deferred revenue   0     0 $ 0    
Non-Central Nervous System, Specified Development And Regulatory Milestone                
Collaborations                
Contingent payments   330,000,000.0            
Product-by-product Sales Milestone                
Collaborations                
Contingent payments   100,000,000.0            
Central Nervous System, Specified Development And Regulatory Milestone                
Collaborations                
Contingent payments   256,000,000.0            
Central Nervous System, Product-by-product Sales Milestone                
Collaborations                
Contingent payments   150,000,000.0            
Delivery of drug supply for commercialization | Grifols                
Collaborations                
Revenue recognized   0   $ 3,300,000        
Collaborative Arrangement                
Collaborations                
Contingent payments   657,100,000            
Collaborative Arrangement | Specified Development Events                
Collaborations                
Contingent payments   195,100,000            
Collaborative Arrangement | Specified Product Launch Events                
Collaborations                
Contingent payments   $ 462,000,000.0            
Strategic collaboration agreement with MDACC | REZLIDHIA                
Collaborations                
Amount due to collaboration partner               $ 15,000,000.0
Collaboration period   5 years            
Payment of cost share to collaboration partner         $ 5,300,000      
Strategic collaboration agreement with CONNECT | REZLIDHIA                
Collaborations                
Amount due to collaboration partner             $ 3,000,000.0  
Collaboration period   4 years